D. Hazuda

D. Hazuda, C. Flexner, S. Swindells, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

D. Hazuda, M. Swanson, D. Graham, 2017, JCI insight.

Robust Antiviral Efﬁcacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees (cid:1)

D. Hazuda, D. Graham, M. Maccoss, 2009 .

Inhibitors of human immunodeficiency virus type I integration

D. Hazuda, 2006, Current opinion in HIV and AIDS.

High resolution photocatalytic mapping of SARS-CoV-2 Spike protein-host cell membrane interactions

D. Hazuda, A. Emili, K. Vora, 2022, bioRxiv.

Characterization of the herpes simplex virus origin binding protein interaction with OriS.

D. Hazuda, W. Mcclements, H. Perry, 1991, The Journal of biological chemistry.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

D. Hazuda, D. Nickle, D. Graham, 2013, Virology.

Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents

D. Hazuda, D. Graham, M. Maccoss, 2010, Antimicrobial Agents and Chemotherapy.

Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase*

D. Hazuda, A. Berghuis, S. Hecht, 2014, The Journal of Biological Chemistry.

Purification of untagged HIV-1 reverse transcriptase by affinity chromatography.

D. Hazuda, M. Lai, Y. Mei, 2010, Protein expression and purification.

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Mark Embrey, Samson M Jolly, Wei Xu, 2004, Proceedings of the National Academy of Sciences of the United States of America.

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.

D. Hazuda, W. Schleif, E. Emini, 2005, Bioorganic & medicinal chemistry letters.

Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells.

Linghang Zhuang, D. Hazuda, W. Schleif, 2003, Journal of medicinal chemistry.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2004, Bioorganic & medicinal chemistry letters.

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells.

H. M. Langford, D. Hazuda, W. Schleif, 2000, Journal of medicinal chemistry.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

D. Hazuda, Jiunn H. Lin, W. Schleif, 2005, Bioorganic & medicinal chemistry letters.

Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.

D. Hazuda, J. Krueger, M. Parniak, 2005, Biochemistry.

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

D. Hazuda, M. Rudd, D. Graham, 2009, Antimicrobial Agents and Chemotherapy.

A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties

Giovanni Migliaccio, D. Hazuda, J. Tomassini, 2004, Antimicrobial Agents and Chemotherapy.

Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.

D. Hazuda, A. Simon, G. McGaughey, 2007, Bioorganic & medicinal chemistry letters.

Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase

D. Hazuda, J. Hastings, A. Wolfe, 1997, Journal of virology.

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

J A Grobler, Amy S. Espeseth, D. Hazuda, 2000, Science.

Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones.

Michael Rowley, Cristina Gardelli, Marco Ferrara, 2007, Journal of medicinal chemistry.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Joseph Kessler, Anthony Carella, D. Hazuda, 2005, Bioorganic & medicinal chemistry letters.

Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

D. Hazuda, R. Cortese, J. Tomassini, 2003, Journal of Biological Chemistry.

Equisetin and a novel opposite stereochemical homolog phomasetin, two fungal metabolites as inhibitors of HIV-1 integrase

D. Hazuda, Sheo B. Singh, D. Zink, 1998 .

Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide.

D. Hazuda, Z. Guan, G. Bills, 2004, Journal of natural products.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.

D. Hazuda, W. Schleif, E. Emini, 2002, Bioorganic & medicinal chemistry letters.

Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes

Amy S. Espeseth, Amy S Espeseth, D. Hazuda, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Integramides A and B, two novel non-ribosomal linear peptides containing nine C(alpha)-methyl amino acids produced by fungal fermentations that are inhibitors of HIV-1 integrase.

D. Hazuda, Z. Guan, K. Silverman, 2002, Organic letters.

Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model.

M. Katharine Holloway, Adam J. Simon, Lixia Jin, 2006 .

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development

D. Hazuda, D. Klein, A. Therien, 2021, PLoS pathogens.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

D. Hazuda, D. Cooper, H. Teppler, 2007, AIDS.

Isolation, Structure, and HIV‐1 Integrase Inhibitory Activity of Xanthoviridicatin E and F, Two Novel Fungal Metabolites Produced by Penicillium chrysogenum.

D. Hazuda, Z. Guan, F. Peláez, 2004 .

Complete Absolute Configuration of Integramide A, a Natural, 16‐mer Peptide Inhibitor of HIV‐1 Integrase, Elucidated by Total Synthesis

D. Hazuda, C. Toniolo, F. Formaggio, 2009, Chembiochem : a European journal of chemical biology.

Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor

Hongtao Xu, D. Hazuda, M. Wainberg, 2010, Journal of Virology.

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold.

D. Hazuda, S. Venkatraman, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors

Christopher L. Daniels, D. Hazuda, Sujata Sharma, 2010, Journal of Virology.

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

Min Xu, D. Hazuda, M. Lai, 2016, Antimicrobial Agents and Chemotherapy.

Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing

Amy S. Espeseth, Min Xu, D. Hazuda, 2021, Proceedings of the National Academy of Sciences.

Generation of a SARS-CoV-2 Replicon as a Model System to Dissect Virus Replication and Antiviral Inhibition

Amy S. Espeseth, Min Xu, D. Hazuda, 2020, bioRxiv.

Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay

D. Hazuda, D. Graham, D. Olsen, 2005, Antimicrobial Agents and Chemotherapy.

Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination

D. Hazuda, A. Therien, Abigail L Reens, 2021, Frontiers in Immunology.

Emerging pharmacology: inhibitors of human immunodeficiency virus integration.

Larissa Wenning, D. Hazuda, M. Iwamoto, 2009, Annual review of pharmacology and toxicology.

Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

D. Hazuda, Daria J Hazuda, 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

Christos J. Petropoulos, Wei Huang, D. Hazuda, 2009, Journal of Virology.

Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

D. Hazuda, C. Coburn, Kristen L G Jones, 2010, Journal of virological methods.

MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW

Qian Huang, D. Hazuda, M. Lai, 2022 .

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Integrastatins: structure and HIV-1 integrase inhibitory activities of two novel racemic tetracyclic aromatic heterocycles produced by two fungal species

D. Hazuda, F. Peláez, P. Felock, 2002 .

Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques

D. Hazuda, J. Shiver, W. Schleif, 2004, Science.

Structure and absolute stereochemistry of HIV-1 integrase inhibitor integric acid. A novel eremophilane sesquiterpenoid produced by a Xylaria sp.

D. Hazuda, K. Silverman, P. Felock, 1999 .

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

D. Hazuda, J. Albrecht, X. Tong, 2013, Virology.

Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay.

D. Hazuda, M. Lai, Michael D Miller, 2008, Analytical biochemistry.

Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.

Xudong Dai, Yudong D. He, Guy Cavet, 2007, Genomics.

In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways

D. Hazuda, M. Lai, Deping Wang, 2014, Antimicrobial Agents and Chemotherapy.

O6 Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least 7 days

Sabrina Fox‐Bosetti, D. Hazuda, A. Hüser, 2017 .

Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery

Paul A Dayton, Russell J Mumper, Anush Sridharan, 2019, Nature Communications.

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

D. Hazuda, M. Swanson, J. Garcia, 2016, The Journal of antimicrobial chemotherapy.

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

D. Hazuda, R. Leavitt, H. Teppler, 2011, Annals of the New York Academy of Sciences.

Inhibitors of human immunodeficiency virus integration

Steven D. Young, D. Hazuda, S. D. Young, 2003 .

Potential new therapies for the treatment of HIV-1 infection.

D. Hazuda, J. Condra, E. Emini, 2002, Annual review of medicine.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

E A Emini, D. Hazuda, W. Schleif, 2001, Bioorganic & medicinal chemistry letters.

Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8-hydroxy-[1,6]-naphthyridine-7-carboxamide inhibitors of HIV-1 integrase.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites

D. Hazuda, Z. Guan, G. Platas, 2003, Journal of Industrial Microbiology and Biotechnology.

P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.

D. Hazuda, Percy Luu, J. Tomassini, 1997, Genes & development.

Human interleukin 1 beta is not secreted from hamster fibroblasts when expressed constitutively from a transfected cDNA

D. Hazuda, P. Young, P. Simon, 1988, The Journal of cell biology.

Detection of Cell-Cell Interactions via Photocatalytic Cell Tagging

Vanessa M. Peterson, David H Perlman, D. Hazuda, 2021, bioRxiv.

Microbiome and Metabolome driven differentiation of TGF-β producing Tregs leads to Senescence and HIV latency

D. Hazuda, M. Lederman, R. Balderas, 2020, bioRxiv.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Gennaro Ciliberto, Peter S Kim, Simon Lennard, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The chemical biology of coronavirus host–cell interactions

D. Hazuda, A. Emili, K. Vora, 2020, RSC chemical biology.

X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platform.

D. Hazuda, Youwei Yan, L. Kuo, 2000, Journal of molecular biology.

siRNA Screening of a Targeted Library of DNA Repair Factors in HIV Infection Reveals a Role for Base Excision Repair in HIV Integration

Amy S. Espeseth, Honglin Zhou, Min Xu, 2011, PloS one.

The Base Excision Repair Pathway Is Required for Efficient Lentivirus Integration

D. Hazuda, A. Espeseth, R. Lloyd, 2011, PloS one.

First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates

Alison R. Gregro, Amy S. Espeseth, Min Xu, 2009, Journal of Pharmacology and Experimental Therapeutics.

First Demonstration of Cerebrospinal Fluid and Plasma A (cid:1) Lowering with Oral Administration of a (cid:1) -Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates □ S

Alison R. Gregro, Amy S. Espeseth, Min Xu, 2008 .

Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication.

D. Hazuda, J. Tomassini, M. Miller, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

D. Hazuda, S. Lewin, R. Sékaly, 2014, PLoS pathogens.

Recommendations for measuring HIV reservoir size in cure-directed clinical trials

R. Siliciano, D. Hazuda, M. Nussenzweig, 2020, Nature Medicine.

Resistance-Associated Amino Acid Variants Associated with Boceprevir plus Pegylated Interferon-α2B and Ribavirin in Patients with Chronic Hepatitis C in the Sprint-1 Trial

D. Hazuda, E. Schiff, J. Albrecht, 2013, Antiviral therapy.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells

D. Hazuda, D. Richman, J. Martinez-Picado, 2018, Science Translational Medicine.

Call for Papers: Drug Resistance in Infectious Diseases and Beyond.

D. Hazuda, C. Schiffer, 2022, ACS infectious diseases.

Recommendations for measuring HIV reservoir size in cure-directed clinical trials

R. Siliciano, F. Bushman, D. Hazuda, 2020, Nature medicine.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

D. Hazuda, D. Richman, F. Hecht, 2015, EBioMedicine.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

D. Hazuda, S. Lewin, F. Hecht, 2019, Nature Communications.

Latency reversal and viral clearance to cure HIV-1

Barton F. Haynes, D. Hazuda, B. Haynes, 2016, Science.

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

Feng Gao, Fangping Cai, Charles B. Hicks, 2010, Antimicrobial Agents and Chemotherapy.

Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation

D. Hazuda, A. Webber, D. Tellers, 2017, Antiviral research.

In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform

D. Hazuda, B. Howell, P. Zuck, 2021, SLAS discovery : advancing life sciences R & D.

PD-1 Blockade in Rhesus Macaques: Impact on Chronic Infection and Prophylactic Vaccination

D. Hazuda, J. Shiver, A. Finnefrock, 2009, The Journal of Immunology.

Evolution of the D-ribose operon on Escherichia coli B/r

A. Ninfa, D. Hazuda, M. Abou-Sabé, 1982, Journal of bacteriology.

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2009, AIDS research and human retroviruses.

Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells

D. Hazuda, Ryan P. Staupe, K. Vora, 2022, Communications biology.

Gag p24 is a Marker of HIV Expression in Tissues and Correlates with Immune Response.

D. Hazuda, H. Hatano, A. Haase, 2021, Journal of Infectious Diseases.

IL-10 driven memory T cell survival and Tfh differentiation promote HIV persistence

D. Hazuda, N. Krogan, R. Balderas, 2021, bioRxiv.

Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

John D. Schreier, Min Xu, D. Hazuda, 2015, Journal of medicinal chemistry.

Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System

D. Hazuda, G. Drusano, Ashley N Brown, 2011, Antimicrobial Agents and Chemotherapy.

Effects of Treatment with Suppressive Combination Antiretroviral Drug Therapy and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid; (SAHA) on SIV-Infected Chinese Rhesus Macaques

D. Hazuda, J. Lifson, M. Piatak, 2014, PloS one.

Combined approaches for HIV cure

D. Hazuda, D. Margolis, 2013, Current opinion in HIV and AIDS.

Vaccinationon Chronic Infection and Prophylactic PD-1 Blockade in Rhesus Macaques: Impact

D. Hazuda, J. Shiver, A. Finnefrock, 2008 .

Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors

D. Hazuda, G. McGaughey, Youwei Yan, 2010, Antimicrobial Agents and Chemotherapy.

“We are looking at the future right now”: community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States

D. Hazuda, L. Montaner, K. Mounzer, 2022, HIV research & clinical practice.

Discovery of natural product inhibitors of HIV-1 integrase at Merck

D. Hazuda, F. Peláez, Sheo B. Singh, 2005 .

Structure, stereochemistry, and biological activity of integramycin, a novel hexacyclic natural product produced by Actinoplanes sp. that inhibits HIV-1 integrase.

D. Hazuda, O. Genilloud, K. Silverman, 2002, Organic letters.

A presenilin‐independent aspartyl protease prefers the γ‐42 site cleavage

D. Hazuda, M. Lai, Ming-Chih Crouthamel, 2006 .

LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease

Shane D. Marine, Amy S. Espeseth, Min Xu, 2006, Proceedings of the National Academy of Sciences.

A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels

Min Xu, Xiao-Ping Shi, Yuanjiang Yu, 2006, Molecular and Cellular Neuroscience.

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions

D. Hazuda, M. Lai, V. Munshi, 2016, Viruses.

Antiviral Activity and In Vitro Mutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

D. Hazuda, G. McGaughey, Youwei Yan, 2012, Antimicrobial Agents and Chemotherapy.

Rational design and synthesis of selective BACE-1 inhibitors.

D. Hazuda, S. Singh, V. Garsky, 2004, Bioorganic & medicinal chemistry letters.

Effect of Suberoylanilide Hydroxamic Acid (SAHA) Administration on the Residual Virus Pool in a Model of Combination Antiretroviral Therapy-Mediated Suppression in SIVmac239-Infected Indian Rhesus Macaques

Octavio A. Quiñones, D. Hazuda, J. Lifson, 2014, Antimicrobial Agents and Chemotherapy.

Effect of SAHA administration on the residual virus pool in a model of combination

Octavio A. Quiñones, D. Hazuda, J. Lifson, 2014 .

SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition.

Adam J. Simon, Georgia B. McGaughey, Philippe G. Nantermet, 2010, Bioorganic & medicinal chemistry letters.

with oral administration of a BACE1 inhibitor in nonhuman primates

Amy S. Espeseth, Adam T. Gates, D. Hazuda, 2008 .

Follicular T cells optimize the germinal center response to SARS-CoV-2 protein vaccination in mice

D. Hazuda, K. Vora, R. Oslund, 2022, Cell Reports.

Vaccine Hyporesponse Induced by Individual Antibiotic Treatment in Mice and Non-Human Primates Is Diminished upon Recovery of the Gut Microbiome

Geoffrey D. Hannigan, D. Hazuda, C. White, 2021, Vaccines.

Vaccine Hyporesponse Induced by Individual Antibiotic Treatment in Mice and Non-Human Primates Is Diminished upon Recovery of the Gut Microbiome

Geoffrey D. Hannigan, D. Hazuda, C. White, 2021, bioRxiv.

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains.

Karen Holmes, Joseph Kessler, Anthony Carella, 2003, Bioorganic & medicinal chemistry letters.

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Failure of AZT: A molecular perspective

D. Hazuda, L. Kuo, 1997, Nature Medicine.

β-Secretase Cleavage at Amino Acid Residue 34 in the Amyloid β Peptide Is Dependent upon γ-Secretase Activity*

Min Xu, Qian Huang, D. Hazuda, 2003, Journal of Biological Chemistry.

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2009, AIDS.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection

D. Hazuda, D. Margolis, N. Archin, 2016, Retrovirology.

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

D. Hazuda, D. Richman, J. Coffin, 2014, The Journal of infectious diseases.

Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening

Cassandra B. Jabara, D. Hazuda, I. James, 2016, Antiviral therapy.

Isolation, structure, and HIV-1 integrase inhibitory activity of Cytosporic acid, a fungal metabolite produced by a Cytospora sp.

D. Hazuda, Z. Guan, P. Felock, 2003, Journal of natural products.

Isolation, structure and HIV-1 integrase inhibitory activity of exophillic acid, a novel fungal metabolite from Exophiala pisciphila.

D. Hazuda, P. Felock, Sheo B. Singh, 2003, The Journal of antibiotics.

Isolation, Structure and HIV‐1 Integrase Inhibitory Activity of Exophillic Acid, a Novel Fungal Metabolite from Exophiala pisciphila.

D. Hazuda, P. Felock, Sheo B. Singh, 2004 .

Discovery, Structure and HIV‐1 Integrase Inhibitory Activities of Integracins, Novel Dimeric Alkyl Aromatics from Cytonaema sp.

D. Hazuda, K. Silverman, F. Peláez, 2002 .

Discovery, structure and HIV-1 integrase inhibitory activities of integracins, novel dimeric alkyl aromatics from Cytonaema sp.

D. Hazuda, K. Silverman, F. Peláez, 2002 .

Chemical and enzymatic modifications of integric acid and HIV-1 integrase inhibitory activity.

D. Hazuda, P. Felock, S. B. Singh, 2000, Bioorganic & medicinal chemistry letters.

Isolation, Structure, and HIV‐1 Integrase Inhibitory Activity of Xanthoviridicatin E and F, Two Novel Fungal Metabolites Produced by Penicillium chrysogenum

D. Hazuda, Z. Guan, F. Peláez, 2003 .

Chemistry and structure-activity relationship of HIV-1 integrase inhibitor integracide B and related natural products.

D. Hazuda, W. Schleif, P. Felock, 2003, Journal of natural products.

Novel mutations introduced at the β-site of amyloid β protein precursor enhance the production of amyloid β peptide by BACE1 in vitro and in cells

Amy S. Espeseth, Min Xu, Qian Huang, 2005 .

Novel mutations introduced at the β-site of amyloid β protein precursor enhance the productio no famyloi d βpeptid eb yBACE 1in vitr oan di ncells

Amy S. Espeseth, Min Xu, Qian Huang, 2005 .

Biochemical and cell-based assays for characterization of BACE-1 inhibitors.

Xiao-Ping Shi, Amy S Espeseth, Min Xu, 2005, Analytical biochemistry.

A novel assay for the DNA strand-transfer reaction of HIV-1 integrase.

D. Hazuda, E. Emini, J. Hastings, 1994, Nucleic acids research.

Total synthesis, characterization, and conformational analysis of the naturally occurring hexadecapeptide integramide A and a diastereomer.

D. Hazuda, C. Toniolo, F. Formaggio, 2010, Chemistry.

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

D. Hazuda, F. Vaida, M. Markowitz, 2009, Antimicrobial Agents and Chemotherapy.

Triple Hyp→Pro replacement in integramide A, a peptaib inhibitor of HIV‐1 integrase: Effect on conformation and bioactivity

D. Hazuda, C. Toniolo, F. Formaggio, 2011, Biopolymers.

Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from the Benchmrk 1 and 2

D. Hazuda, 2008 .

Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration.

D. Hazuda, K. Stillmock, J. Grobler, 2009, Methods.

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2017, Oncotarget.

A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2006, Bioorganic & medicinal chemistry letters.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

D. Hazuda, E. Asante-Appiah, A. Howe, 2016, Antimicrobial Agents and Chemotherapy.

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Characterization of a soluble stable human cytomegalovirus protease and inhibition by M-site peptide mimics

D. Hazuda, R. Lafemina, A. Marcy, 1996, Journal of virology.

Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.

M Katharine Holloway, Lixia Jin, Michelle Crouthamel, 2006, Journal of medicinal chemistry.

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates

D. Hazuda, E. Asante-Appiah, C. Petropoulos, 2021, Antimicrobial agents and chemotherapy.

Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1

Min Xu, D. Hazuda, M. Bukhtiyarova, 2023, Science Translational Medicine.

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

D. Hazuda, A. Webber, D. Margolis, 2020, Journal of Virology.

Altering Expression Levels of Human Immunodeficiency Virus Type 1 gp120-gp41 Affects Efficiency but Not Kinetics of Cell-Cell Fusion

D. Hazuda, A. Simon, J. Lineberger, 2002, Journal of Virology.

A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage.

D. Hazuda, M. Lai, Ming-Chih Crouthamel, 2006, Journal of neurochemistry.

Primary Human Dendritic Cells and Whole-Blood Based Assays to Evaluate Immuno-Modulatory Properties of Heat-Killed Commensal Bacteria

D. Hazuda, Gokul Swaminathan, Dario A Gutierrez, 2021, Vaccines.

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

Qian Huang, Adam T. Gates, D. Hazuda, 2014, Antimicrobial Agents and Chemotherapy.

Microbiome And Metabolome Driven Differentiation Of TGF-β Producing Tregs Leads to Senescence and HIV Latency

D. Hazuda, M. Lederman, R. Balderas, 2021 .

[791] HCV ANTIVIRAL ACTIVITY AND RESISTANCE ANALYSIS IN CHRONICALLY INFECTED CHIMPANZEES TREATED WITH NS3/4A PROTEASE AND NS5B POLYMERASE INHIBITORS

D. Hazuda, D. Graham, J. Vacca, 2007 .

Radiosynthesis of the HIV integrase inhibitor [18F]MK‐0518 (Isentress)

D. Hazuda, H. Burns, W. J. Thompson, 2010 .

Mechanisms of Human Immunodeficiency Virus Type 1 Concerted Integration Related to Strand Transfer Inhibition and Drug Resistance

D. Hazuda, Krishan Kumar Pandey, D. Grandgenett, 2008, Antimicrobial Agents and Chemotherapy.

8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

Emerging Pharmacology: Inhibitors of Human

D. Hazuda, M. Iwamoto, L. Wenning, 2009 .

Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells.

Min Xu, Qian Huang, D. Hazuda, 2005, Journal of Alzheimer's disease : JAD.

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

D. Hazuda, W. Schleif, E. Emini, 2001, Bioorganic & medicinal chemistry letters.

Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors.

D. Hazuda, A. Simon, Hemaka A. Rajapakse, 2010, Bioorganic & medicinal chemistry letters.

Localization and Membrane Topology of Coronavirus Nonstructural Protein 4: Involvement of the Early Secretory Pathway in Replication

D. Hazuda, B. Cullen, N. DeLuca, 2007, Journal of Virology.

High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface.

D. Hazuda, A. Emili, K. Vora, 2023, Cell chemical biology.

Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.

John D. Schreier, Min Xu, D. Hazuda, 2017, Bioorganic & medicinal chemistry letters.

Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

John D. Schreier, Min Xu, D. Hazuda, 2016, Journal of Medicinal Chemistry.

BACE-1 inhibition by a series of ψ[CH2NH] reduced amide isosteres

M. Katharine Holloway, Adam J. Simon, Lixia Jin, 2006 .

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

D. Hazuda, C. Petropoulos, R. Danovich, 2009, Journal of Virology.

Combined approaches for HIV cure

D. Hazuda, D. Margolis, 2013, Current opinion in HIV and AIDS.

In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways

D. Hazuda, M. Lai, Deping Wang, 2014, Antimicrobial Agents and Chemotherapy.

Activity profile-based siRNA screen to explore the functional genomics of Alzheimer's disease

Shane D. Marine, Amy S. Espeseth, Min Xu, 2007 .

Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques.

C. Deming, D. Hazuda, M. Lederman, 2013, The Journal of clinical investigation.

Purification, solution properties and crystallization of SIV integrase containing a continuous core and C-terminal domain.

D. Hazuda, L. Kuo, Z. Chen, 1999, Acta crystallographica. Section D, Biological crystallography.

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency

D. Hazuda, M. Swanson, D. Graham, 2015 .

Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

D. Hazuda, C. Flexner, S. Swindells, 2018, The International Journal of Tuberculosis and Lung Disease.